STAAR Surgical (NASDAQ:STAA) Now Covered by Wells Fargo & Company

Wells Fargo & Company started coverage on shares of STAAR Surgical (NASDAQ:STAA - Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage issued an equal weight rating and a $17.00 target price on the medical instruments supplier's stock.

Several other research analysts also recently weighed in on STAA. Canaccord Genuity Group reduced their target price on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. StockNews.com lowered shares of STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Finally, Stifel Nicolaus reduced their target price on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $24.25.

STAAR Surgical Trading Up 0.8 %

STAA traded up $0.15 on Monday, reaching $18.03. The stock had a trading volume of 442,678 shares, compared to its average volume of 793,064. The business's 50-day moving average price is $17.19 and its two-hundred day moving average price is $22.94. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $49.86. The company has a market cap of $889.33 million, a P/E ratio of -43.98 and a beta of 0.75.

Insider Activity at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68. Following the completion of the purchase, the insider now owns 11,289,437 shares in the company, valued at approximately $174,873,379.13. The trade was a 0.32 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders acquired 1,742,581 shares of company stock worth $28,407,543. Corporate insiders own 1.00% of the company's stock.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $180,000. GAMMA Investing LLC increased its position in shares of STAAR Surgical by 4,086.0% in the 1st quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier's stock valued at $258,000 after purchasing an additional 14,301 shares during the last quarter. Bridgefront Capital LLC raised its holdings in shares of STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 2,306 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of STAAR Surgical during the 4th quarter worth $278,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of STAAR Surgical during the fourth quarter worth $292,000. Institutional investors and hedge funds own 96.70% of the company's stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.